Fast reaction and long duration—application of dabrafenib plus trametinib in treatment of metastatic melanoma with B-Raf V600E mutation: A case report
The prognosis of patients with advanced melanoma is poor. The five-year recurrence rate is approximately 70%, whereas the overall survival rate is only 4%–10%. We report the case of a 61-year-old male patient with metastatic melanoma (B-Raf+). The tumor load of the patient was significantly reduced...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KeAi Communications Co. Ltd.
2021-12-01
|
| Series: | Chinese Journal of Plastic and Reconstructive Surgery |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2096691121001096 |